Advanced search
Show most relevant results first | Most recent results are first | Show use by person

Results 1-3 of 3 for drugs segment:8801812

Written Answers — Department of Health: Medicinal Products (17 Jan 2024)

Seán Sherlock: ...for Health the criteria for a medicine reimbursement application to be considered by the HSE’s products committee for reimbursement; the criteria for a medicine to be considered by the HSE’s Drugs Group; and if he will make a statement on the matter. [56569/23]

Written Answers — Department of Health: Medicinal Products (17 Jan 2024)

Stephen Donnelly: The Rapid Review process has been a core component of the NCPE’s assessment pathway for 14 years. It facilitates the identification of drugs which require additional assessment in the form of a full Health Technology Assessment (HTA), while maintaining a robust appraisal of the relevant clinical and economic evidence for drugs which do not require further assessment. It allows for...

Written Answers — Department of Health: Medicinal Products (17 Jan 2024)

Stephen Donnelly: ...from EMA approval to HSE reimbursement approval does not consider this important factor and misrepresents the process, as statutorily the HSE is precluded from approving or assessing a drug for reimbursement a drug until an application is received from the company holding the market authorisation. When an application is made to have a product added to the reimbursement list in Ireland,...

   Advanced search
Show most relevant results first | Most recent results are first | Show use by person